Onyx Pharmaceuticals Inc (ONXX)

[surf1944]

8:04AM Onyx Pharma: Nexavar in combination with chemotherapy shown to extend progression-free survival in patients with advanced breast cancer (ONXX) : Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals (ONXX) announce that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.